Private Trust Company’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $45.2K | Buy |
209
+9
| +5% | +$1.72K | ﹤0.01% | 1424 |
|
|
2026
Q1 | $36.7K | Buy |
200
+25
| +14% | +$4.61K | ﹤0.01% | 1435 |
|
|
2025
Q4 | $30.8K | Buy |
175
+20
| +13% | +$3.27K | ﹤0.01% | 1468 |
|
|
2025
Q3 | $21.7K | Sell |
155
-11
| -7% | -$1.49K | ﹤0.01% | 1609 |
|
|
2025
Q2 | $20.8K | Sell |
166
-63
| -28% | -$7.85K | ﹤0.01% | 1546 |
|
|
2025
Q1 | $31.3K | Buy |
229
+98
| +75% | +$14K | ﹤0.01% | 1374 |
|
|
2024
Q4 | $20K | Sell |
131
-120
| -48% | -$20.2K | ﹤0.01% | 1485 |
|
|
2024
Q3 | $48.7K | Sell |
251
-226
| -47% | -$47.3K | ﹤0.01% | 1148 |
|
|
2024
Q2 | $111K | Sell |
477
-481
| -50% | -$105K | 0.01% | 841 |
|
|
2024
Q1 | $207K | Buy |
958
+399
| +71% | +$93.4K | 0.02% | 635 |
|
|
2023
Q4 | $145K | Sell |
559
-35
| -6% | -$8.6K | 0.02% | 716 |
|
|
2023
Q3 | $153K | Buy |
594
+35
| +6% | +$9.36K | 0.02% | 649 |
|
|
2023
Q2 | $159K | Buy |
559
+36
| +7% | +$10.7K | 0.02% | 640 |
|
|
2023
Q1 | $145K | Buy |
523
+62
| +13% | +$17.2K | 0.02% | 643 |
|
|
2022
Q4 | $128K | Sell |
461
-15
| -3% | -$4.24K | 0.02% | 652 |
|
|
2022
Q3 | $127K | Sell |
476
-7
| -1% | -$1.49K | 0.02% | 593 |
|
|
2022
Q2 | $99K | Buy |
+483
| New | +$98.7K | 0.02% | 697 |
|
|
2022
Q1 | – | Sell |
-1,232
| Closed | -$296K | – | 351 |
|
|
2021
Q4 | $296K | Sell |
1,232
-91
| -7% | -$23.4K | 0.04% | 325 |
|
|
2021
Q3 | $374K | Sell |
1,323
-35
| -3% | -$11.5K | 0.05% | 307 |
|
|
2021
Q2 | $470K | Sell |
1,358
-302
| -18% | -$91.5K | 0.07% | 273 |
|
|
2021
Q1 | $464K | Sell |
1,660
-41
| -2% | -$11.1K | 0.08% | 264 |
|
|
2020
Q4 | $416K | Sell |
1,701
-209
| -11% | -$53.9K | 0.07% | 268 |
|
|
2020
Q3 | $541K | Buy |
+1,910
| New | +$533K | 0.1% | 215 |
|
|
2020
Q2 | – | Sell |
-664
| Closed | -$210K | – | 355 |
|
|
2020
Q1 | $210K | Buy |
+664
| New | +$202K | 0.05% | 316 |
|
|
2019
Q2 | – | Sell |
-1,584
| Closed | -$374K | – | 372 |
|
|
2019
Q1 | $374K | Buy |
1,584
+131
| +9% | +$41.3K | 0.08% | 269 |
|
|
2018
Q4 | $437K | Sell |
1,453
-61
| -4% | -$19.5K | 0.1% | 227 |
|
|
2018
Q3 | $534K | Buy |
1,514
+52
| +4% | +$17.9K | 0.11% | 225 |
|
|
2018
Q2 | $424K | Buy |
1,462
+57
| +4% | +$16K | 0.09% | 252 |
|
|
2018
Q1 | $384K | Buy |
1,405
+106
| +8% | +$32.9K | 0.08% | 266 |
|
|
2017
Q4 | $413K | Buy |
1,299
+504
| +63% | +$162K | 0.09% | 260 |
|
|
2017
Q3 | $248K | Buy |
795
+31
| +4% | +$9.18K | 0.05% | 325 |
|
|
2017
Q2 | $207K | Buy |
+764
| New | +$202K | 0.05% | 347 |
|
|
2014
Q4 | – | Sell |
-497
| Closed | -$164K | – | 395 |
|
|
2014
Q3 | $164K | Buy |
497
+23
| +5% | +$7.58K | 0.06% | 306 |
|
|
2014
Q2 | $149K | Buy |
474
+16
| +3% | +$4.82K | 0.05% | 334 |
|
|
2014
Q1 | $140K | Buy |
458
+70
| +18% | +$22.2K | 0.05% | 301 |
|
|
2013
Q4 | $108K | Sell |
388
-1
| -0.3% | -$259 | 0.04% | 295 |
|
|
2013
Q3 | $94K | Buy |
389
+9
| +2% | +$2.01K | 0.04% | 302 |
|
|
2013
Q2 | $82K | Buy |
+380
| New | +$81.2K | 0.04% | 312 |
|
Other funds holding BIIB
Private Trust Company's BIIB Position: Q2 2026 in Review
Private Trust Company increased its Biogen (BIIB) stake by 4.5% in Q2 2026, buying an estimated $1.72K and bringing the position to 209 shares worth $45.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1424.
Private Trust Company first reported a position in BIIB in Q2 2013 and has held it in 38 quarters since. The position peaked at $541K in Q3 2020. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Private Trust Company held 209 shares of Biogen worth $45.2K as of Q2 2026.
- Private Trust Company bought 9 Biogen shares in Q2 2026, an estimated $1.72K.
- Biogen made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #1424 holding.
- Private Trust Company first reported a position in Biogen in Q2 2013 and has held it in 38 quarters since.
- Private Trust Company's Biogen position peaked at $541K in Q3 2020.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.